

# Invitation to presentation of Isofol's year-end report 2021 on February 24, 2022

GOTHENBURG, Sweden, February 14, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) ("Isofol"), will publish the company's year-end report 2021 on Thursday, February 24, 2022. On the same day, Isofol invites investors, analysts, and media to an audiocast with a subsequent question time.

In conjunction with the publication of the year-end report 2021, Isofol invites investors, analysts, and media to an audiocast on February 24, at 11:00 a.m. CET. The presentation will be held by Isofol's CEO Ulf Jungnelius and CFO Gustaf Albèrt, who will present and comment the report, followed by a Q&A-session. The presentation will be held in English.

### Date and time

February 24, 2022, at 11:00 a.m. CET

#### **Audiocast link**

https://tv.streamfabriken.com/isofol-medical-q4-2021

#### Phone number

To participate via telephone, please dial one of the numbers below.

SE: +46850558352 UK: +443333009034 US: +16467224904

The presentation will also be available on Isofol's website after the broadcast: <a href="https://isofolmedical.com/company-presentations/">https://isofolmedical.com/company-presentations/</a>

## For further information, please contact

## Isofol Medical AB (publ)

Ulf Jungnelius, M.D., Chief Executive Officer E-mail: jungnelius@isofolmedical.com

Phone: +46 (0) 709 16 89 55

Gustaf Albèrt, CFO

E-mail: gustaf.albert@isofolmedical.com

Phone: +46 (0)709-16 83 02

The information was submitted for publication, through the agency of the contact person set out above, at 09.10 CET on February 14, 2022.



# **About Isofol Medical AB (publ)**

Isofol Medical AB (publ) is a clinical stage biotech company developing arfolitixorin to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer by increasing tumor response and progression free survival. Isofol holds a worldwide exclusive license agreement with Merck KGaA, Darmstadt, Germany to develop and commercialize arfolitixorin for oncology indications. Isofol Medical AB (publ) is traded on the Nasdaq Stockholm.

www.isofolmedical.com